Dr. Gonzalez-Martin on the Results of the PRIMA Trial in Ovarian Cancer

Video

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the results of the phase III PRIMA trial in advanced ovarian cancer.

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the results of the phase III PRIMA trial in advanced ovarian cancer.

Data presented at the 2019 ESMO Congress demonstrated that frontline maintenance therapy with niraparib (Zejula) improved median progression-free survival (PFS) by 5.6 months versus placebo in patients with newly diagnosed, advanced platinum-sensitive ovarian cancer.

Investigators conducted a hierarchical analysis of patients with homologous recombination deficiency (HRD), which, if positive, would prompt analysis of the overall population, says Gonzalez-Martin. Among patients with HRD, the median PFS was 21.9 months with niraparib versus 10.4 months with placebo (HR, 0.43; 95% CI, 0.50-0.76; P <.001). The median PFS in the overall population was 13.8 months in the niraparib arm versus 8.2 months in the placebo arm, which translated to a 38% reduction in the risk of progression or death with the addition of the PARP inhibitor (HR, 0.62; 95% CI, 0.50-0.76; P <.001).

<<< View more from the 2019 ESMO Congress

Related Videos
Gottfried Konecny, MD
Patrick I. Borgen, MD
Gottfried E. Konecny, MD, lead clinician, gynecologic oncology, Department of Medicine, the University of California, Los Angeles
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology